The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis
Open accessAbstract
BACKGROUND.: Differentiated thyroid cancer has a good prognosis and only rarely presents with distant metastasis at diagnosis. The clinical outcome of this presentation was assessed with respect to survival and factors that may determine prognosis. METHODS.: A retrospective review was undertaken of patients with stage M1 differentiated thyroid cancer at presentation (n = 49), referred from 1980–2000 at a single institution. RESULTS.: The median age was 68 (range, 17–90), with 69% females. The initial site(s) of metastasis were lung only, 45%, bone only, 39%, other single site, 4%, and multiple sites, 12%. Histology: papillary, 51%, follicular, 49%. Initial treatment(s) included: thyroidectomy, 82%, radioactive iodine (RAI), 88%, excision of metastasis, 29%, radiotherapy, 47%, and chemotherapy, 6%. With a median follow‐up time of 3.5 years, 25 patients are alive (51%) and 24 died (49%), with 3‐year and 5‐year actuarial survivals of 69% and 50%, respectively. Only a minority of patients (4/25, 16%) had no clinical evidence of disease at last follow‐up. Most deaths (17/24, 71%) were due to progressive cancer. Prognosis was associated with age, site of metastasis, histology, and iodine avidity of the metastasis. Patients aged ≤45 (n = 8) had a 3‐year survival of 100%, versus 62% for those age > 45 years (P = .001). The 3‐year survival for lung only versus bone only metastasis was 77% versus 56% (P = .02); for papillary versus follicular carcinoma, 75% versus 62% (P = .006); for iodine‐avid disease (n = 29) versus not avid (n = 14), 82% versus 57% (P = .02), respectively. In multivariate analysis after adjusting for age, only histology and iodine avidity remained significant for survival. The hazard ratio for follicular histology was 3.7 (95% confidence interval [CI], 1.1–12.1, P = .03), and for tumors not avid for iodine, 3.4 (95% CI, 1.2–9.2, P = .02). CONCLUSIONS.: The data support the aggressive management of patients presenting with stage M1 thyroid cancer, with thyroidectomy and RAI. Complete clinical eradication of disease was rarely seen, and 50% of patients survived for more than 5 years. Young patients with papillary tumors and/or iodine‐avid disease have an even better prognosis. Cancer 2007. © 2007 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer
Mazzaferri, E. L., & Jhiang, S. M. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90321-2 · Cited by 2,635
Hundahl, S. A., Fleming, I. D., Fremgen, A. M., & Menck, H. R. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1 · Cited by 1,836
HAY, I. D., Bergstralh, E. J., Goellner, J. R., Ebersold, J. R., & Grant, C. S. (1993) · PubMed · Cited by 1,223
MARTIN, S., MAURICE, T., VATHAIRE, F. D., CATHERINE, H., GARDET, P., TRAVAGLI, J.-P., FRAGU, P., LUMBROSO, J., CAILLOU, B., & PARMENTIER, C. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-4-960 · Cited by 552
RUEGEMER, J. J., HAY, I. D., BERGSTRALH, E. J., RYAN, J. J., OFFORD, K. P., & GORMAN, C. A. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-3-501 · Cited by 389
Shoup, M., Stojadinovic, A., Nissan, A., Ghossein, R. A., Freedman, S., Brennan, M. F., Shah, J. P., & Shaha, A. R. (2003) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(03)00332-6 · Cited by 280
Dinneen, S. F. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.7.2041 · Cited by 275
Differentiated thyroid cancer presenting initially with distant metastasis
R. Shaha, A., P. Shah, J., & R. Loree, T. (1997) · The American Journal of Surgery · doi:10.1016/s0002-9610(97)00158-x · Cited by 273
Brierley, J., Tsang, R., Panzarella, T., & Bana, N. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02358.x · Cited by 189
Self-citationLa Quaglia, M. P., Black, T., Holcomb, G. W., Sklar, C., Azizkhan, R. G., Haase, G. M., & Newman, K. D. (2000) · Journal of Pediatric Surgery · doi:10.1053/jpsu.2000.6935 · Cited by 173
Zettinig, G., Fueger, B. J., Passler, C., Kaserer, K., Pirich, C., Dudczak, R., & Niederle, B. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01482.x · Cited by 164
Decaussin‐Petrucci, M., Bernard, M. H., Adeleine, P., Treilleux, I., Peix, J. L., PUGEAT, M. M., TOURNIAIRE, J., & Berger, N. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200208000-00005 · Cited by 63
Sasatomi, E., Tokunaga, O., & Miyazaki, K. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19961115)78:10<2184::aid-cncr21>3.0.co;2-u · Cited by 40
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas
Melo, M., da Rocha, A. G., Vinagre, J., Batista, R., Peixoto, J., Tavares, C., Celestino, R., Almeida, A., Salgado, C., Eloy, C., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3734 · Cited by 555
Thyroid Cancer Epidemiology and Prognostic Variables
Sipos, J. A., & Mazzaferri, E. L. (2010) · Clinical Oncology · doi:10.1016/j.clon.2010.05.004 · Cited by 514
Metadata
- Authors
- Sampson, E., Brierley, J. D., Le, L. W., Rotstein, L., & Tsang, R. W.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2007-08-17
- Volume
- 110
- Issue
- 7
- Pages
- 1451-1456
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1999324180
- Cited by
- 295
- References
- 15
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.